Figeac Aéro Reaffirms All Financial Targets
Bitget2026/10/29 16:48- Figeac Aéro reaffirmed all financial targets, with its start to the year in line with its annual objective.
- The group remained on track for 2028 revenue above EUR 600 million and EBITDA above EUR 100 million.
- Revenue reached EUR 111.8 million, with organic growth of 11.6%, marking a 21st consecutive quarter of growth.
- The order backlog reached a record EUR 5 billion, supported by continued commercial momentum.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
